Bicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) saw an uptick in trading volume on Monday . 315,799 shares traded hands during trading, a decline of 5% from the previous session’s volume of 332,084 shares.The stock last traded at $24.60 and had previously closed at $27.02.

Analyst Ratings Changes

Several analysts have recently weighed in on BCYC shares. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and set a $48.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Monday. Finally, Royal Bank of Canada began coverage on shares of Bicycle Therapeutics in a research note on Friday, September 6th. They set an “outperform” rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.56.

Bicycle Therapeutics Stock Down 0.2 %

The stock’s 50-day moving average price is $23.24 and its 200-day moving average price is $22.99. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -5.47 and a beta of 0.90. The company has a current ratio of 14.77, a quick ratio of 14.77 and a debt-to-equity ratio of 0.01.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.33. The firm had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. Bicycle Therapeutics’s quarterly revenue was down 17.9% compared to the same quarter last year. On average, sell-side analysts expect that Bicycle Therapeutics plc will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,194 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $19.64, for a total transaction of $62,730.16. Following the sale, the chief executive officer now directly owns 384,076 shares in the company, valued at $7,543,252.64. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 4,555 shares of company stock valued at $89,460 over the last three months. 8.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCYC. BNP Paribas Financial Markets boosted its holdings in Bicycle Therapeutics by 10,489.4% in the fourth quarter. BNP Paribas Financial Markets now owns 36,851 shares of the company’s stock valued at $666,000 after acquiring an additional 36,503 shares in the last quarter. Trexquant Investment LP grew its stake in shares of Bicycle Therapeutics by 177.6% during the 4th quarter. Trexquant Investment LP now owns 196,323 shares of the company’s stock valued at $3,550,000 after purchasing an additional 125,604 shares during the period. Westfield Capital Management Co. LP bought a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at about $16,585,000. Armistice Capital LLC grew its stake in shares of Bicycle Therapeutics by 53.6% during the 4th quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock valued at $27,771,000 after acquiring an additional 536,000 shares during the period. Finally, Platinum Investment Management Ltd. boosted its stake in Bicycle Therapeutics by 26.8% in the 4th quarter. Platinum Investment Management Ltd. now owns 362,080 shares of the company’s stock worth $6,546,000 after purchasing an additional 76,601 shares during the period. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.